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[~  Does Chlamydophila pneumoniae play a role in Cystic Fibrosis? 
S.M. Schmidt 1 , C.E. Miiller 1 , E.H. Ballke 1 , C. Birr 2, K. Breuel 3, R. Bruns 1 , 
J. Hein 4, J. Mainz 5, A. Tacke 6, S.K.W Wiersbitzky 1 . Children ~' and Youth 
Hospitals', 1 University of Gre~'wal& 2Schwerin; 3 University of Rostock, 
4Rehabilitation Hospital, Wustrow; 5University of Jena; 6Berlin-Buch, Germany 
Aims: In children with therapy-refractory bronchitis or pneumonia bronchial 
Chlamydophila (Cp.) pneumoniae-infection is common and is associated with 
pathological lung function. Cystic fibrosis (CF) is a hereditary illness and chronic 
respiratory tract symptoms as well. The aim was to study the prevalence of 
Cp. pneumoniae infection and a potential association with progression i CE 
Methods: In a multicenter study, Cp. pneumoniae was detected in sputum by 
polymerase chain reaction with enzyme immunoassay detection and in paired serum 
samples with microimmunofluorescence test. Lung function tests and clinical score 
characterized impairment of CE 
Results: C~p. pneumoniae-infection was detected in 22 of 63 CF patients. It was 
associated with P aeruginosa co-infection (21/22 versus 23/41; p 0.001) and 
obstructive disturbance in 60 cooperative patients with pulmonary function tests 
(20/20 versus 29/40; p 0.01). In 22 patients with at least six months follow-up a 
trend line was calculated for every lung function parameter and clinical score by 
linear logistic regression i cluding all tests. Six months loss of FEV1 was higher in 
sixteen @. pneumoniae positives ( 2.11 [ 5.04; 1.15] versus 1.63 [ 0.24; 3.04], 
p 0.008, quartiles of per cent predicted) as well as decrease in Kraemer clinical 
score ( 0.251 [ 0.39; 0.068] versus 0 [ 0.104; 0.408], p 0.03). A P aeruginosa 
detection was associated with a higher exacerbation rate in six months (0.812 [0; 
1.21] versus 0 [0; 0.189], p 0.059), however, differences in lung function and 
clinical score were insignificant. 
Conclusions: @. pneumoniae co-infection may play a role in CE 
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~ Intravenous antibiotics effects on spirometrics parameters of 
cystic fibrosis (CF) patients with acute pulmonary exacerbation 
infected with Pseudomonas aeruginosa 
C.I.S. Santos 2, M.A.G.O. Ribeiro 2, S.R.M. Paula 2, R.T. Mendes 1, A.F. Ribeiro 1 , 
A.T. Tresoldi 1, A.M. Morcillo 1 , J.D. Ribeiro 1 . 1Department of Pediatrics, 
2physiotherapy, State University of Campinas Medical School, Unicamp, Brazil 
CF patients when chronically infected with P aeruginosa present frequently pul- 
monary exacerbation. 
Aim: to evaluate the immediate ffect of intravenous antibiotic therapy on pul- 
monary function tests, cardio respiratory parameters and clinical scores in CF 
patients colonized with P aeruginosa immediately before and after treatment of 
acute pulmonary exacerbation. 
Methods: A clinical, prospective study including 21 CF patients colonized with 
le aeruginosa t the CF Center of State University of Campinas Medical School, 
Brazil, were studied. Pulmonary function tests, SaO 2 measured by pulse oximetry, 
clinical evaluation and appliance of Cystic Fibrosis Clinical Score (CFCS) and 
Cystic Fibrosis Foundation (CFF) pulmonary exacerbation signs were investigated, 
immediately before the treatment with intravenous antibiotics (step I). The same 
procedure was done two weeks later after treatment, in all patients (step II). 
Results: 21 patients (11 females), aged 7 28 years (16.14±6.36) completed the 
study. Using Shwachman score, 10 patients were classified as severe, 9 as moderate 
and 2 mild. The data show a statistic significant improvement in the CFCS and 
CFF scores evaluations (31.71 + 6.65 vs 18.81 + 4); (6 + 1.92 vs 0.48 + 0.68, 
p < 0.01). 
Conclusion: Intravenous antibiotics are effective and improve pulmonary function 
tests and Clinical Scores of Cystic Fibrosis in pulmonary exacerbations of CF pa- 
tients. 
• Remote monitoring in the early detection of pulmonary 
exacerbation in Cystic Fibrosis 
S. Sarfaraz, N.A. Jarad. Adult CF Centre, Bristol Royal Infirmary, Bristol 
BS2 8HW, UK 
Aims: Pulmonary exacerbation is an important outcome in research and clinical 
settings. Published evidence and consensus i lacking in the criteria used to define 
pulmonary exacerbations. Definition of exacerbation differs between physicians 
(Higgs, S Jarad, NA. Thorax. 2005;60. sup II). The aim of this study is to investigate 
change in symptoms and FEV1 in CF patients in the period around pulmonary 
exacerbation, using a remote monitoring device. 
Methods: The remote monitoring device used is a portable computer/mobile phone 
attached to a spirometer. Patients are asked to complete once daily a scoring of their 
cough, sputum, breathlessness and fatigue symptoms on a scale of 1 4. They also 
perform spirometry at the same time. Data is sent automatically on a real time basis 
and can be viewed via a secure website. Data produced on the first exacerbation- 
free 15 days are regarded as baseline data. Exacerbations were regarded to have 
occurred if patient sought help from the CF team, or if they hah 3 days increase 
in three respiratory symptoms, or two respiratory symptoms and 10% decline in 
FEV1 or three days of decline in FEV1 alone. 
Results: So far 43 patients were enrolled in the study. Their mean age is 24.2 years 
(range 15 34). A total of 48 pulmonary exacerbations have been reported so far, 
31 exacerbations (64.58°/0) were detected by the system, 14 exacerbations (35.41°/0) 
were missed by the system. This was due to non-compliance (9), and technical 
problems (5). Three exacerbations (6.25°/0) were false positives. 
Conclusion: This is the first system that has been used to objectively detect 
pulmonary exacerbations in CF. The rate of adherence to recording varies between 
male and female CF patients. So far the system has demonstrating itself to be a 
useful tool in the remote monitoring of Cystic Fibrosis. 
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• Longitudinal monitoring of infective exacerbations in Cystic 
Fibrosis by sputum Calprotectin: from biomarker discovery to 
clinical application 
R.D. Gray 1,2, M. Imrie 1,2, A.C. Boyd 2, J.A. Innes 1 , D. Porteous 2,A.R Greening 1 .
1Department of Respiratory Medicine, Western General Hospital, 2Medical 
Genetics', University of Edinburgh, Edinburgh, UK 
Aims: It is difficult to monitor accurately therapeutic benefit of treatments in Cystic 
Fibrosis (CF). Measurements such as FEV1 distinguish poorly between established 
lung damage and active inflammation. We have previously demonstrated the 
presence of Calprotectin i  CF sputum using SELDI TOF (surface nhanced laser 
desorption time of flight) mass spectrometry. Specialised proteomics techniques are 
a valuable research tool but have limited clinical application. We have investigated 
the utility of an ELISA measure for sputum Calprotectin in the monitoring of an 
infective xacerbation. 
Methods: 23 patients attending the Scottish Adult CF centre were recruited at the 
time of an exacerbation requiring intravenous antibiotics. Sputum was collected at 
the start and end of antimicrobial therapy. Sputum Calprotectin levels were assayed 
with ELISA. Further analysis was also performed on SELDI TOE 
Results: Sputum Calprotectin levels decreased significantly with antibiotic therapy 
from 4.7(0.6)mg/ml to 1.8(0.4) [mean(SEM)] at p<0.001. Protein profiles on 
SELDI TOF also changed with therapy. Sputum cytology revealed neutrophils 
predominantly in excess of 90% at the beginning and end of therapy. 
Conclusions: These data suggest that Calprotectin levels in sputum reflect he un- 
derlying level of inflammation i the CF lung, and this can be monitored by ELISA 
as well as SELDI TOE Proteomics identified sputum markers, such as Calprotectin, 
may provide more accurate means of assessing the ongoing inflammatory burden in 
the CF lung than currently used methods and are therefore valuable in identifying 
and monitoring responses to standard or new therapies 
